

Althea Group Holdings Ltd

16:25 07 Feb 2019

Althea enters UK medicinal cannabis market through acquisition

Althea Group Holdings Ltd (ASX:AGH) has entered the UK medicinal cannabis market with the acquisition of its new UK subsidiary, Althea MMJ UK Ltd.

The company will be one of the first companies to enter the medicinal cannabis market in that country following the November 2018 legislative change, enabling cannabis-based products to be prescribed by doctors.

Althea's UK entry has been supported by Aphira Inc (TSX:APH) which has entered into a new cannabis product acquisition agreement and trademark licence agreement with Althea UK.

These agreements will provide Althea UK with high-quality and consistent medicinal cannabis supply allowing the company to focus on patient access and product distribution.

Improving patient access to medicinal cannabis

Althea CEO Joshua Fegan said: "The UK's highly regulated framework for prescribing, supplying and possessing medicinal cannabis products is very similar to that of Australia."

"We know focusing on improving patient access to medicinal cannabis and educating medical practitioners on treatment is the key to establishing market share, so the UK market entry will be based on our three-phased business model successfully implemented in Australia."

Since entering the Australian market in May 2018, 93 registered healthcare professionals are now prescribing Althea medicinal cannabis products to more than 328 patients across Australia.

This represents about 20% of the total market.


Globally unique approach

Fegan added: "Focused on early revenue generation through importation and distribution of products, the education of healthcare professionals and scalable

Price: A\$0.445

Market Cap: A\$90.47M

1 Year Share Price Graph



September 2018 December 2018 February 2019

Share Information

Code: AGH

Listing: ASX

52 week High Low
A\$0.76 A\$0.18

Sector: Cannabis

Website: www.althea.com.au

Company Synopsis:

Althea Group Holdings (ASX:AGH) is a patient-focussed medical cannabis company.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

long-term supply of high-quality products, our approach is unique globally.

"The model can be rolled out in other countries where patient access is similarly highly regulated."

Althea plans to export Althea's Australian manufactured products for UK distribution by 2020.

- Jessica Cummins

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek personal advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.